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Invariant natural killer T (iNKT) cells are one of the innate lymphocytes that regulate 
immunity, although it is still elusive how iNKT cells should be manipulated for transplant 
tolerance. Here we describe the potential of a novel approach using a ligand for iNKT cells 
and sub-optimal dosage of antibody for CD40-CD40 ligand (L) blockade as a powerful 
method for mixed chimerism establishment after allogenic bone marrow transplantation in 
sub-lethally irradiated fully-allo recipients. Mixed chimera mice accepted subsequent 
cardiac allografts in a donor-specific manner. High amounts of Th2-cytokines were detected 
right after iNKT-cell activation, while subsequent IFN-γ production by NK cells was 
effectively inhibited by CD40/CD40L blockade. Tolerogenic-components, such as 
CD11clowmPDCA1+ plasmacytoid dendritic cells and activated regulatory T cells (Tregs) 
expressing CD103, KLRG-1 and PD-1, were subsequently augmented. Those activating 
Tregs seem to be required for the establishment of chimerism because depletion of the 
Tregs one day before allogenic cell-transfer resulted in a chimerism brake. These results 
collectively suggest that our new protocol makes it possible to induce donor-specific 











Invariant natural killer T (iNKT) cells are a small subset of lymphocytes that is 
characterized by Vα14-Jα18 invariant TCR, which recognizes glycolipid molecules, e.g. a 
synthetic ligand α-galactsylceramide (α-GalCer)—to date the most potent iNKT-cell ligand—
loaded on a non-classical MHC class I-like molecule, CD1d(1, 2). Upon stimulation by α-
GalCer, iNKT cells quickly secrete enormous amounts of cytokines within hours(3, 4), both 
type 1 helper T (Th1) cytokines (e.g. IFN-γ, IL-12), which activate cytotoxic reactions, and 
less harmful type 2 helper T (Th2) cytokines (e.g. IL-4, IL-10), which are thought to regulate 
immunity(5).  
 
In the field of transplantation, iNKT cells are considered to be crucial in some experimental 
models of transplant tolerance, such as cornel allograft survival(6, 7), rat xen-islets 
acceptance induced by anti-CD4 mAb(8), thymic chimerism induction with 
cyclophosphamide(9), cardiac graft tolerance induced by anti-CD40L(10, 11), and mixed 
hematopoietic chimerism induction(12, 13). Even though it has been accepted that iNKT 
cells are responsible for the promotion and/or maintenance of transplant tolerance, how 
iNKT cells should best be activated for tolerance induction still remains unclear. Indeed, 
some negative effects of iNKT-cell activation have been reported in several transplant 
experiments(10, 14-16). These results are caused by the enhancement of cytotoxicity 
and/or Th1-cell responses including IFN-γ production generated by iNKT-cell activation. 
Indeed, the skewing of Th2-cytokines by iNKT-cell activation using some α-GalCer 
analogues that do not enhance IFN-γ production(17), resulted in the delay of cardiac 
allograft rejection(18). Taken together, it is suggested that the treatment of iNKT cells 
should be controlled to enhance production of Th2-cytokines and to reduce the production 
of Th1-cytokines.  
 It is well known that presentation of α-GalCer by dendritic cells (DCs) to iNKT cells leads 
to the production of large amounts of IFN-γ(19). In contrast to aqueous α-GalCer, the 
liposomal formulation of α-GalCer (αGC-liposomes) could be preferentially incorporated into 
the B-cell subset of CD21highCD23low phenotype and play a role in the suppression of helper 
T-cell priming and the development of IL-10-producing regulatory T cells (Tregs)(20). Based 
on these results, αGC-liposomes were assessed by using murine models of acute graft 
versus host disease (GvHD). It was confirmed that αGC-liposomes had a significant 
prophylactic effect in parallel with allo-specific Tregs expansion in vivo(21).  
 
In this study, αGC-liposomes were tested using a mixed chimerism model that is a reliable 
method for transplant tolerance induction. Treatment with αGC-liposomes resulted in the 
complete acceptance of transplanted donor bone marrow without GvHD and the cardiac 
allograft from the same donor permanently when combined with sublethal total body 
irradiation (TBI) followed by co-stimulation blockade. This novel protocol made it possible to 










Materials and Methods 
Animals 
WT BALB/c (H-2d), C57BL/6 (B6, H-2b), and C3H/He (H-2k) mice were purchased from 
Japan Slc. Inc. Vα14 NKT-deficient mice (BALB/c Jα18−/−), described elsewhere(1), were 
backcrossed for more than nine generations. All mice were bred and maintained in our 
animal facilities under specific pathogen-free conditions. An internal committee on the use 
and care of laboratory animals approved of all experiments (IRB12-76).  
 
Reagents 
Aqueous α-GalCer (KRN7000) was purchased from Kirin Brewery Co. Ltd, Japan. 
Liposomal formulation of α-GalCer was provided by REGiMMUNE(Japan). Doses of both 
formulations of α-GalCer were expressed based on the dose of contained α-GalCer and 
calculated assuming a mouse body weight of 20g. Both formulations of α-GalCer were 
diluted in Hanks’ Balanced Salt Solution (HBSS; Life Technologies, USA) for intravenous 
(i.v.) injection. Anti-CD40L mAb (MR-1), anti-CD25 mAb (PC61.5.3), anti-IL4 mAb (11B11), 
and anti-IL-10 mAb (JES5-2A5) were purchased from BioXcell (USA) and diluted in 
Dulbecco’s Phosphate-Buffered Saline (DPBS; Life Technologies) for intraperitoneal (i.p.) 
administration.  
 
Bone Marrow Transplantation (BMT)  
Femur and tibia were harvested from B6 donor mice and flushed with HBSS using a 21-
gauge needle to collect bone marrow cells (BMCs). Age-matched (8-12 week) BALB/c 
recipients underwent non-myeloablative TBI (3 Gy) using an X-ray irradiation system 
(Hitachi MBR-1520R-3; Hitachi Medical Co. Japan) 3-4 h prior to i.v. injection of 2.0 × 107 
unseparated B6 BMCs. 
 FACS Staining 
Heparinized blood or tissue samples were hemolyzed with ACK Lysing Buffer (Lonza, USA) 
to remove red cells. The cell pellets were incubated at 4ºC for 20 m with saturating 
concentrations of mAb mixtures: TCR-β, B220, Mac-1, Gr-1, CD4, CD8, CD25, CD44, 
CD49b, CD62L, CD69, CD103, ICOS, KLRG-1, PD-1 (BD Pharmingen, USA), CD11b, 
CD11c (eBioscience, USA), mPDCA1 (Miltenyi Biotech, Germany), and α-GalCer pre-
loaded CD1d-tetramer (Proimmune, UK). FITC-conjugated anti-H-2Kb and PE-conjugated 
anti-H-2Kd (eBioscience) were used for chimerism analysis. All mouse cells were incubated 
with purified CD16/32 (BD Pharmingen) to block unspecific staining. For the detection of 
intracellular antigen, anti-Foxp3 (Miltenyi Biotech), anti-IFN-γ, anti-Ki-67, anti-CTLA4, and 
anti-Bcl-2 (BD Parmingen) were stained after fixation/permeabilization using the Foxp3 
Staining Buffer Set (eBioscience). Cell samples were analyzed with a BD FACSCantoTM II 
flow-cytometer (BD Biosciences, USA). Chimerism was analyzed in mononuclear cells 
gated by forward and orthogonal light scatter. The percentage of donor cells was calculated 
as follows: (%H-2Kb donor cells) / (%H-2Kb donor cells + %H-2Kd host cells).  
 
Heterotopic Cardiac Transplantation 
All transplant procedures were performed with the animals under general anesthesia. Fully 
vascularized heterotopic cardiac grafts from B6 donors were transplanted into BALB/c 
recipients using microsurgical techniques(22). Postoperatively, graft function was assessed 
daily by palpation for evidence of contraction. Rejection was defined as complete cessation 
of contractions and confirmed by direct visualization. Cardiac allografts of tolerant mice 
were removed 100 d after transplantation and studied histologically. Formalin-fixed sections 
(4-µm thick) were cut, mounted on silane-coated slides and stained with hematoxylin-eosin 
or Masson-trichrome stain.  
 
Mixed Lymphocyte Reaction (MLR) 
As a responder, CD4+ or CD8+ T cells were negatively isolated with CD4/CD8 negative 
isolation kit (Life Technologies) from the splenocytes obtained from recipient mice. As a 
stimulator, antigen presenting cells (APCs) were prepared from the splenocytes of naïve 
mice by T-cell depletion with mouse pan-T beads (Life Technologies) and then irradiated 
30Gy. Isolated T cells were incubated with stimulator at a 1:2 responder:stimulator ratio in 
RPMI 1640 medium (Life Technologies) containing 10% fetal bovine serum, 10mM Hepes, 
1 x L-glutamine (2mM), 1 x Na pyruvate (1μM), 1 x penicillin-streptomycin (1μM), and 0.5 x 
antibiotic/mycotic (all from Life Technologies). For ELISpot assay, 96 well Multi-Screen 
plates (Millipore,USA) were coated with mouse IFN-γ capture antibody (R&D system,USA), 
incubated at 4ºC overnight. Responder CD8+T cells were added to wells containing 
irradiated APCs and incubated for 42 h. Mouse IFN-γ detection antibody was added and 
incubated at 4 ºC overnight and then visualized with ELISPot Blue Color Mudule (R&D).  
 
Cytokine Measurements 
Serum samples were collected from recipient mice at 2 h and 20 h after BMT. Serum IL-4, 
IL-10, IL-12, and IFN-γ were determined by multicytokine detection system (Bio-Rad, USA) 
following the manufacturer’s instructions. They were measured using a Luminex System 
and calculated using Bio-plex software.  
 
Statistical Analysis 
Statistical data were analyzed with Prism 4 software (GraphPad Software, Inc. USA) using 
the Student’s t test (unpaired, two-tailed). Kaplan-Meier survival curves were analyzed 


























Combination treatment of iNKT-cell ligand with CD40-CD40L blockade induces 
durable mixed chimerism 
Allogenic BMCs derived from B6 (H-2b) mice were administered intravenously into 
sublethal TBI-treated BALB/c (H-2d) mice, and a proportion of grafted donor cells 
expressing H-2b in peripheral blood mononuclear cells (PBMCs) was analyzed by flow-
cytometer (Figure.1A). Grafted donor cells were undetectable two weeks after BMT in 
untreated mice. Consistent with other transplant models that showed negative effects of α-
GalCer(10, 14-16), mice treated with αGC-liposomes alone also showed immediate graft 
rejection. It has been proved that CD40-CD40L interaction is essential for the IFN-γ 
production of iNKT cells(23), which may promote graft rejection caused by α-GalCer 
stimulation. Therefore, we attempted a combination therapy of αGC-liposomes and anti-
CD40L mAb. Anti-CD40L is a co-stimulation blockade commonly used to induce transplant 
tolerance and is generally combined with T-cell depletion (TCD) mAb(24), donor-specific 
transfusion(25-28), or other co-stimulation blockades such as CTLA4-Ig(29, 30). However, 
in our fully-allo combination, single administration of 0.5mg anti-CD40L on d 0 failed to 
engraft donor cells. Even when tested with 2.0mg anti-CD40L, mixed chimerism induction 
was observed in only 20% of mice. On the other hand, combination treatment of αGC-
liposomes with 0.5mg anti-CD40L resulted in substantial preservation of the grafted cells. 
Grafted donor cells in these chimera mice remained durable for over 100 d (Figure.1B). 
The mice maintained the grafted donor cells not only in the peripheral blood but also in the 
spleen, lymph nodes, and bone marrow for over 100 d (Figure.1C). Substantial numbers of 
donor-derived multi-lineages including T cells, B cells, macrophages, and granulocytes 
were observed (Figure.1D). The result indicated that mixed chimerism could be established 
in mice treated with a combination of αGC-liposomes with a sub-optimal dosage of anti-
CD40L. 
 
Mixed chimerism-established mice accept cardiac allograft from the same donor 
To test the capability of graft survival extension, treated recipient mice were transplanted 
with heterotopic cardiac allografts from the same donor mice two weeks after BMT 
(Figure.2A). In the case of H-2d–restricted recipients that were transferred H-2b-restricted 
BMCs with 0.5mg anti-CD40L alone, the H-2b-restricted cardiac graft was rejected 
immediately. Even in mice treated with 2.0mg anti-CD40L alone, the cardiac graft was 
rejected gradually. In contrast, H-2d-restricted recipient mice transferred H-2b-restricted cells 
with αGC-liposomes plus 0.5mg anti-CD40L completely accepted the H-2b-restricted 
cardiac graft. Histopathlogical analysis of the tolerant mice at 100 d showed neither cellular 
infiltration nor vascular fibrosis, both of which were observed in the grafts obtained from 
mice treated with 2.0mg anti-CD40L (Figure.2C). To test whether the cardiac graft survival 
achieved by αGC-liposomes plus anti-CD40L was restricted to the allogenecity of 
transferred BMCs, a 3rd-party strain-derived cardiac graft was transplanted. As expected, all 
cardiac grafts of C3H/He (H-2k) mice were rejected (Figure.2B). These data collectively 
suggest that the mixed chimerism established by a single injection of donor BMCs with 
αGC-liposomes plus a sub-optimal dosage of anti-CD40L could induce donor-specific, long-
term transplant tolerance, whereas it could not be achieved by anti-CD40L monotherapy, 
even using optimal-dosage. 
 
αGC-liposomes plus anti-CD40L treatment diminishes allo-reactivity toward both 
host and donor in vitro  
We examined allo-reactivity of T cells derived from the treated mice by using an in vitro 
system of MLR. First, splenic CD8+T cells were recovered 28 d after BMT and then co-
cultured with irradiated APCs of splenocytes derived from BALB/c or B6 mice. The number 
of IFN-γ-producing cells was determined by ELISpot system. Splenic CD8+T cells derived 
from untreated and either αGC-liposomes- or anti-CD40L-treated mice produced numerous 
IFN-γ-positive spots upon stimulation by H-2b APCs, but not by H-2d APCs (Figure.3A). On 
the other hand, the CD8+T cells from mice treated with a combination of αGC-liposomes 
with anti-CD40L did not produce IFN-γ-positive spots upon either H-2b or H-2d APCs 
stimulation. In addition, splenic CD4+T cells were enriched, labeled with CFSE, and then 
co-cultured with H-2b or H-2d APCs. As expected from the results of the CD8+T cells, 
proliferation capability of CD4+T cells of mice treated with both αGC-liposomes and anti-
CD40L were deficient upon stimulation by either H-2b or H-2d APCs (Figure.3B). On the 
other hand, the proliferation of CD4+T cells from mice treated with αGC-liposomes alone or 
anti-CD40L alone was comparable to that from untreated mice. Taken together, combination 
therapy that uses αGC-liposomes and anti-CD40L might make it possible to reduce allo-
reactivity of the recipient mice toward host and donor in vitro, which is essential for graft 
survival as well as prevention of GvHD. 
 
αGC-liposomes plus anti-CD40L treatment deviates immunity toward Th2 and 
facilitates engraftment of donor cells 
The administration of iNKT-cell ligand, α-GalCer, is known to result in the immediate 
secretion of multivalent cytokines. In our previous study, the production capability of Th2-
cytokines such as IL-4 and IL-10 in iNKT cells was enhanced by treatment with αGC-
liposomes rather than aqueous α-GalCer(20). To elucidate the correlation of the cytokine 
production and the establishment of mixed chimerism, representative cytokines such as IL-
4, IL-10, IL-12, and IFN-γ in the serum of untreated- and treated-mice were assessed 
(Figure.4A). The production of all cytokines was clearly elevated 2 h after BMT in the 
recipient mice treated with both formations of α-GalCer, but not with anit-CD40L alone. The 
amounts of all cytokines tested in αGC-liposomes-treated mice were much higher 
compared to those in aqueous α-GalCer-treated mice. As a result, the rate of chimerism 
establishment and the proportion of engrafted donor cells in PBMCs of the BMT-mice 
treated with αGC-liposomes plus anti-CD40L were significantly higher compared to those 
with aqueous α-GalCer plus anti-CD40L (Figure.4B). At 20 h after BMT, IFN-γ production 
was enhanced in recipient mice treated with either αGC-liposomes alone or aqueous α-
GalCer alone. By contrast, the expression of IFN-γ was remarkably diminished 20 h after 
BMT in the recipient mice treated with either αGC-liposomes plus anti-CD40L or aqueous α-
GalCer plus anti-CD40L.These data collectively suggest that the production of IL-4 and/or 
IL-10, but not IFN-γ generated by a ligand for iNKT cells might be relevant to the 
establishment of mixed chimerism. CD40-CD40L blockade antibodies could be 
indispensable for the reduction of IFN-γ production after iNKT-cell activation. 
 
Anti-CD40L is required for abrogation of interaction between iNKT cells and NK cells 
It is known that iNKT-cell activation is followed by high amounts of IFN-γ production by NK 
cells. To clarify whether anti-CD40L inhibited production of IFN-γ from iNKT cells or NK 
cells, splenocytes obtained from mice treated with αGC-liposomes with/without anti-CD40L 
were analyzed by intracellular IFN-γ cytostaining (Figure.5). At 90 m after αGC-liposome 
administration, production of IFN-γ in iNKT cells was already observed in mice treated 
without anti-CD40L. This production of IFN-γ was also shown even in mice treated with 
anti-CD40L. In NK cells, production of IFN-γ was not observed yet at this time in all animals 
(data not shown). At 6 h after treatment, IFN-γ production of iNKT cells had already 
vanished in both mice treated with/without anti-CD40L (data not shown). Instead, NK cells 
in mice treated with αGC-liposomes alone started to produce IFN-γ. On the other hand, 
mice treated with αGC-liposomes plus anti-CD40L lacked this IFN-γ production of NK cells. 
Taken together, we presumed that anti-CD40L blocked NK-cell activation following iNKT-cell 
activation, although it could not directly inhibit IFN-γ production from iNKT cells themselves. 
 
αGC-liposomes plus anti-CD40L treatment augments plasmacytoid DCs 
To elucidate the relevance of soluble mediators for mixed chimerism establishment, 
neutralization mAb of IL-4 or IL-10 was administrated one day before BMT (Table 1). 
Contrary to expectation, achievement rate of mixed chimerism was still stably observed 
after those treatments. The data suggested there were other factors which facilitated 
engraftment caused by αGC-liposomes.  
We previously reported that mice treated with αGC-liposomes but not aqueous α-GalCer 
showed augmentation of plasmacytoid DCs (pDCs), which could induce activating Tregs in 
vivo and in vitro(20). Thus, we focused on the change of those cellular components in 
untreated- and treated-mice by flow-cytometer. In our current study, conventional myeloid 
DCs (mDCs) were defined as CD11b+CD11chigh population among the lineages (CD3, 
CD19, CD49b, NK1.1, and TER-119)-negative population (Figure6.A). As mPDCA1+ 
subpopulation mostly consisted of CD11clow cells and showed characteristics of immature 
DCs on their cell surface (Figure.6B), the cells corresponded to pDCs. In the splenocytes 
obtained from mice treated with αGC-liposome and/or anti-CD40L 3 d before, the injection 
of αGC-liposomes preferentially augmented the proportion of splenic pDCs rather than that 
of mDCs (Figure.6C&D). This augmentation of pDCs was not abrogated or enhanced by 
anti-CD40L. 
 αGC-liposomes plus anti-CD40L treatment activates and expands Tregs 
Next, we analyzed CD4+CD25highFoxp3+T-cell population in splenocytes of untreated- and 
treated-mice 30 d after BMT by flow-cytometer (Figure.7A). Consistent with previous 
reports, the proportion of Treg phenotype cells was increased with statistical significance in 
both mice treated with αGC-liposomes alone and in those with αGC-liposomes plus anti-
CD40L treatment (Figure.7B). To elaborate on the proliferation activity of those expanded 
Tregs, intracellular Ki-67 expression of Tregs was compared among each group. Strikingly, 
Tregs in chimera mice treated with αGC-liposome plus anti-CD40L showed remarkable up-
regulation of Ki-67 compared to those of other treated groups that had rejected the donor 
graft. Further analysis showed that Tregs in the chimera mice were fully activated because 
the expression of CD44, CD69, CD103, ICOS, KLRG-1, and PD-1 on the cell surface and 
intracellular CTLA-4 were up-regulated, while that of CD62L in the cell surface and 
intracellular Bcl-2 were down-regulated (Figure.7C). These results collectively suggest that 
activated Tregs could be expanded in the mixed chimera mice generated by combination 
therapy with αGC-liposomes plus anti-CD40L.  
 
Tregs activated by iNKT cells are indispensable for induction of mixed chimerism  
To clarify the importance of Tregs in the process of the establishment of mixed chimerism, 
we administered anti-CD25 mAb to deplete Tregs at the day before BMT. Mixed-chimera 
establishment was completely abrogated by Tregs depletion at the day before BMT 
(Figure.8A). To confirm that establishment of mixed chimerism and expansion of activating 
Tregs in our model is induced by iNKT cells, experiments were performed using Jα18−/− 
iNKT cell-deficient mice as a recipients. As expected, iNKT cell-deficient recipient mice 
failed to retain donor-derived cells and to activate Tregs (Figure.8A&B). Taken together, 
this suggests that activation of Tregs just after BMT might be indispensable for 
establishment of mixed chimerism and may be regulated by recipient-derived iNKT cells 
























The induction of mixed hematopoietic chimerism is a powerful and effective means to 
achieve transplant-tolerance. A growing body of the literature suggests that inhibition of T-
cell function using TCD mAb and/or co-stimulatory blockade is fundamental for engraftment 
of allogeneic hematopoietic cells(12, 24, 25, 29, 31-33). However, such approaches non-
specifically inhibit T-cell dependent immunity, including the regulatory mechanism that is 
important for establishment of tolerance. We reported here a novel approach that could 
establish mixed chimerism by boosting regulatory mechanisms with iNKT-cell activation 
under CD40/CD40L blockade. 
 
Anti-CD40L in this study seems to be a switch that could control immune-direction of 
iNKT cells after α-GalCer activation. However, Matsuda et al reported that CD40/CD40L 
signaling is not crucial for the initial IFN-γ production from iNKT cells because IFN-γ 
production from iNKT cells could be detected at 2 h after α-GalCer administration in both 
WT and CD40-/- mice(3). Consistent with this, administration of anti-CD40L in our study 
also could not abrogate IFN-γ production of iNKT cells at 90 m after α-GalCer 
administration (Figure.5). It is thought that following initial activation, iNKT cells express 
CD40L and then cross-link with CD40 on DCs(34, 35), which results in the production of IL-
12 by DCs. Therefore, we speculated that anti-CD40L blocked this process and abrogated 
DCs maturation. Indeed, IFN-γ production from NK cells, which follows after IL-12 
production of CD40high mature-DCs, was inhibited by anti-CD40L in the current study 
(Figure.5). NK cells are considered to be deeply related to hematopoietic cell rejection(36-
40), and have a reciprocal relationship with Tregs(41, 42). Hence, we presume that 
blockade of NK-cell activation with anti-CD40L is indispensable for tolerance induction. 
 
Although some mice treated with a combination of aqueous α-GalCer plus anti-CD40L 
showed engraftment of donor cells, the achievement rate of mixed chimerism observed in 
those mice is significantly poorer as compared to mice treated with αGC-liposomes plus 
anti-CD40L. The difference between liposomal and aqueous formulations of α-GalCer on 
the immune response is ascribed to the profile of the APCs incorporated. As reported 
previously, αGC-liposomes are incorporated into splenic B-cell fractions more than 
CD11c+DCs and involved in IL-10 production of B cells(20). Smedt et al showed that IL-10 
affected during the maturation of DCs down-regulated their capacity of producing IL-12 and 
activating Th1 cells(43). Bezbradica et al demonstrated that α-GalCer -presenting B cells 
weakened not only DCs maturation but also DCs-mediated activation of iNKT cells and NK 
cells(44). Furthermore, Veronique et al also reported that production of IL-12 by DCs was 
reduced after the interaction with B cells(45). Together, one might speculate that B cell-
derived IL-10 induced by αGC-liposomes could inhibit maturation of DCs in the micro-
environment. These results collectively suggest that αGC-liposomes and anti-CD40L work 
complementally to block DCs maturation and to relatively augment pDCs (Figure.6C&D), 
which are designated as immature tolerogenic DCs producing IL-10 and functionally 
different from the CD11chi mDCs that produce IL-12(46). 
 
It has been reported that pDCs could develop the antigen-specific IL-10 producing Tregs 
in vivo and in vitro(26, 46). In our regimen, the development of CD4+CD25highFoxp3+ T cells 
was observed (Figure.7A&B). It is noteworthy that the CD4+CD25highFoxp3+ T cells 
expressed activation markers like CD103 and KLRG-1 (Figure.7C). KLRG-1+ Tregs are 
considered to be recent Ag-responsive and highly activated phenotypes with enhanced 
suppressive function(47-49). Furthermore, in our study, the CD4+CD25highFoxp3+ T cells 
expressed a high level of PD-1 (Figure.7C), which is considered to be linked to IL-10 
production(13). Since the depletion of CD25+ T cells on the day before BMT abrogated the 
mixed chimerism induction (Figure.8A), we conclude that the CD4+CD25highFoxp3+ T cells 
expanded by our regimen could be activated functional Tregs. 
 
The importance of Tregs for peripheral tolerance induction has been proved(26, 28). 
However, the role of Tregs in the mixed chimerism induction model still remains unclear. In 
several reports, mixed chimerism induction was not abrogated by anti-CD25 mAb 
treatment(30, 50). In those studies, the impact of Treg-depletion might be insufficient to 
induce allogeneic hematopoietic cell rejection because they used stronger immune 
suppression or lower immunological barrier models than ours. Other supportive studies 
described the abrogation of mixed chimerism induction with anti-CD25 mAb in the lower 
invasive protocol setting of fully-allo combination(27, 51). It is presumable that there is a 
delicate balance between Tregs and effector T cells (Teffs) in allograft tolerance. 
 
 Tregs themselves are thought to have the ability to induce chimerism because adoptive 
transfer of ex vivo expanding donor-specific or even polyclonal Tregs enables mixed 
chimerism and graft tolerance(52). In those protocols, however, preconditioning or 
immunosuppression, e.g. 5Gy TBI(53) combined with anti-CD40L plus CTLA4-Ig—with(54) 
or without(55) rapamycin—are needed to some extent to suppress the allo-reactivity of Teffs. 
The ratio of Tregs to antigen-specific Teffs has been previously identified as a predictor of 
the potential protective effects of Tregs(28, 56). From those data, it is speculated that allo-
reactivity could be regulated, and allo-hematopoietic cell engraftment would be facilitated 
when the number and activity of Tregs overcome those of Teffs. This might be achieved by 
inhibiting Teffs with TCD-mAbs or co-stimulation blockades. Another approach is to 
augment the number of functional Tregs, which could be achieved by the regime we 
present in this study.  
 
Concerning the clinical indication of our protocol, clinical application of anti-CD40L has 
been hampered by thrombolic complication(57). However, development of anti-CD40 (e.g. 
4D11(58, 59), 3A8(60), and more recently, 2C10(61)) has progressed. Those antibodies are 
not only alternatives for anti-CD40L, but rather more suitable for our protocol, because they 
can directly affect DCs, which are responsible for unfavorable Th1-immunity caused by α-
GalCer stimulation. 
 
 Because the amino acids of CD1d and invariant TCR, which are important for binding with 
α-GalCer, are well conserved among species such as the mouse and human(62-64), α-
GalCer can be used to activate both mouse and human iNKT cells. Thus, our protocol could 
be applied to clinical trials just as it is. α-GalCer has already been used in clinical studies 
for patients with advanced cancer and chronic hepatitis B/C(65, 66). Immunological effects 
induced by the administration of α-GalCer were observed, especially in the subgroup of 
patients with relatively high pre-treatment circulating iNKT-cell numbers. Meanwhile, the low 
number of iNKT cells likely contributed to the lack of immunoreactivity after α-GalCer 
administration. For those unresponsive patients, novel approaches such as transfer of in 
vitro α-GalCer -pulsed DCs(67-69) or autologous iNKT cells generated in vitro(65, 70) have 
shown to be more potent than α-GalCer administration alone. Those data are valuable for 
clinical indication of αGC-liposomes, although the effect of αGC-liposomes on human cells 
should be investigated closely.  
 Our data suggest a new insight—that the immune direction of iNKT cells is controlled 
through a type of APCs presenting α-GalCer and co-stimulation signals, and that it is 
possible to enhance our innate ability of immune tolerance by appropriate activation of iNKT 
cells. We hope that not only transplant tolerance but also prevention of other immune 
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Figure 1. Combination treatment of αGC-liposomes plus anti-CD40L establishes 
multi-organ/multi-lineage durable mixed hematopoietic chimerism. BALB/c mice were 
grafted with B6 2.0x107 bone marrow cells after 3Gy total body irradiation. Single dose of 
anti-CD40L mAb i.p. injected right after BMT at the dose indicated; 10 μg/kg αGC-
liposomes injected via tail vein within 30 m after BMT. (A) FACS analysis of PBMCs carried 
out two weeks after BMT to assess the establishment of mixed chimerism. Summary of 
percentage of donor (H-2b) cells among PBMCs calculated from individual mice from five 
independent experiments. (B) Percentage of donor cells in PBMCs of individual mice 
treated with αGC-liposomes plus anti-CD40L followed on d 30, 60, and 100 after BMT. (C) 
Mononuclear cells isolated from peripheral blood, spleen, superficial lymph nodes, and 
bone marrow obtained from chimera mice 100 d after BMT. Left, representative figures of 
dot plots of H-2Kb versus H-2Kd staining in each organ; Right, mean percentages ± SD of 
H-2Kb positive donor cells in each organ. (D) Multilinage chimerism in PBMCs as analyzed 
from chimera mice 100 d after BMT. Left, representative figures of dot plots in each linage. 
T cells, B cells, macrophages, and granulocytes indicated as TCR-β, B220, MAC-1, and Gr-
1 positive cells, respectively. Right, mean percentage ± SD of H-2Kb positive donor cells in 
each linage. Data are representative of five independent experiments. αGC-liposomes: 
liposomal formulation of α-galactsylceramide; PBMCs: peripheral blood mononuclear cells; 
BMT: bone marrow transplantation. 
 
Figure 2. Combination therapy of αGC-liposomes plus anti-CD40L induces cardiac 
allograft tolerance in donor-specific manner. 
(A) BALB/c (H-2d) mice-transplanted heterotopic cardiac allograft from B6 (H-2b) donor 14 d 
after B6 bone marrow transfer with 0.5mg anti-CD40L alone (N=6, black dot line), with 
2.0mg anti-CD40L alone (N=6, blue dashed line), or with combination therapy of αGC-
liposomes and 0.5mg anti-CD40L (N=6, red solid line). (B) Chimera mice-transplanted 
heterotopic cardiac allograft from B6 (H-2b) donor (N=6, red solid line) or C3H/He (H-2k) 
donor (N=8, blue dot line) after B6 bone marrow transfer with αGC-liposomes plus 0.5mg 
anti-CD40L. Graft survival curves of each group; P-values calculated by log-rank test. (C) 
All mice with beating grafts were sacrificed on d 100 after cardiac transplantation and 
examined histopathologically. Representative histopathology of cardiac grafts obtained from 
mice grafted from syngenic donors (left column), grafted from B6 donors after B6 bone 
marrow transfer with 2.0mg anti-CD40L alone (middle column) and with αGC-liposomes 
plus 0.5mg anti-CD40L (right column).  
 
Figure 3. T cells of mixed chimera mice show hypo-responsiveness toward donor 
antigen as well as toward host antigen 
(A) CD8+T cells obtained from bone marrow-transplanted mice co-cultured with H-2b or H-
2d-restricted APCs. IFN-γ secreting cells were captured and recognized as spots by 
ELISpot assay. Left: data presented are mean number ± SD of IFN-γ secreting cells among 
1 x 105 CD8+T cells calculated from triplicated wells of each treated group. Right, 
photographs are representative of one in triplicated wells of each group. (B) CD4+T cells 
obtained from bone marrow-transplanted mice stained with CFSE, then co-cultured with H-
2b or H-2d-restricted APCs. Four days later, dilution of CFSE in CD4+T cells was compared 
among each group. Data represent one of three independent experiments. APC: antigen 
presenting cell; CFSE: carboxyfluorescein succinimidyl ester. 
 
Figure 4. αGC-liposomes plus anti-CD40L treatment enhances Th2 cytokine 
production and donor cell engraftment compared to aqueous α-GalCer plus anti-
CD40L. (A) Serum samples collected from recipient mice of each treatment group at 2 h 
(white bar) and 20 h (black bar) after BMT, and serum concentration of IL-4, IL-10, IL-12, 
and IFN-γ as measured using Bio-Plex cytokine assay. N.D: not determined; data 
presented are mean cytokine concentrations ± SD (pg/mL). Data represent one of three 
independent experiments. (B) BALB/c mice-transplanted B6 bone marrow with 
administration of αGC-liposomes or aqueous α-GalCer with 0.5mg anti-CD40L; the α-
GalCer contained in 10 μg/kg in both formulations. Two weeks after BMT, the establishment 
of chimerism was assessed by flow-cytometer. Percentage of donor cells in PBMCs of 
individual mice from three independent experiments and p-value as calculated by unpaired 
t-test. α-GalCer: aqueous α-galactsylceramide; αGC-liposome: liposomal formulation of α-
galactsylceramide. 
 
Figure 5.  IFN-γ production of NK cells after iNKT-cell activation are inhibited by 
anti-CD40L 
Splenocytes were obtained from mice administrated with αGC-liposomes with or without 
anti-CD40L 90 m or 6 h before, then stained with cell surface molecules to define iNKT cells 
(as double positive of α-GalCer pre-loaded CD1d-tetramer and TCR-β) and NK cells (as 
CD49b+ and TCR-β- ). Representative histogram of IFN-γ expression of each mouse 
detected in iNKT cells (top, 90 m after treatment) and NK cells (bottom, 6 h after treatment). 
Gray filled line: isotype control. Data represent one of two independent experiments.  
 
Figure 6. αGC-liposomes augment the proportion of splenic CD11clowmPDCA1+ cells 
rather than that of CD11chi DCs. αGC-liposomes and/or anti-CD40L were injected into 
BALB/c mice, of which splenocytes were then obtained after 3 d. For DCs staining, 
collagenase D was injected into the spleen obtained from recipient mice and incubated at 
37 ºC for 30 m before suspension. (A) The following biotinated antibodies were stained with 
streptavidin and used to gate out lineages: CD3e, CD19, CD49b, NK1.1, and TER-119 (left 
dot plots). Then, mDCs were defined as CD11b+CD11chigh population (mid dot plots) and 
pDCs were defined as CD11clowmPDCA1+ population (right dot plots). (B) To confirm 
characteristics of both pDCs and mDCs defined in this study, expression level of I-Ad, 
CD62L, CD80, CD86, and CD40 on their cell surface were analyzed by flow-cytometer. 
Representative histograms of CD11b+CD11chigh cells (top) and mPDCA1+CD11clow cells 
(bottom) obtained from mice treated with αGC-liposomes plus anti-CD40L (black line); 
naïve BALB/c mice controls (gray dashed line); Isotype controls (filled histogram). (C) 
Representative dot plots of CD11C(+)Lineage(-) population in each treated group. 
Proportion of mDCs and pDCs indicated as % CD11b+ cells and % mPDCA1+ cells, 
respectively. (D) Proportion of the mDC (left) and that of pDC (right) among the 
CD11c(+)lineage(-) cells in the each treatment group. The data summarizes 4 or 5 mice 
from each group covering three independent experiments; P-values as calculated by 
unpaired t-test.  
 
Figure 7. Expansion and activation of CD4+CD25highFoxp3+ Tregs in chimera mice 
induced by αGC-liposomes plus anti-CD40L treatment. (A) Splenocyte obtained from 
each group 30 d after BMT stained with CD4/CD25/Foxp3/Ki-67. Top, representative dot 
plots in each group gated by CD4-positive cells; CD4+CD25highFoxp3+ cells confirmed as 
Tregs. Bottom, histograms representative of Ki-67 expression of CD4+CD25highFoxp3+ 
gated cells in each group.  (B) Statistical analysis of quantitative and qualitative difference 
of Tregs among each group. Mean percentage of Tregs in CD4+ T cells (left) and mean 
population of Ki-67high in Tregs (right). Data are summarized from three independent 
experiments; P-values calculated by unpaired t-tests. (C) Splenocytes obtained from 
chimera mice at 30 d after BMT stained with CD4/CD25/Foxp3 together with each cell 
surface or intracellular molecules. Representative histograms of each molecule expressed 
on the cells gated with CD4+CD25highFoxp3+. As a control, splenocytes obtained from naïve 
BALB/c mice were stained. Chimera mice: black unfilled line; control naïve BALB/c mice: 
gray filled line. Data are representative of one of three independent experiments. ICOS: 
inducible T cell co-stimulator; KLRG-1: killer cell lectin-like receptor subfamily G, member-1; 
PD-1: programmed cell death-1; CTLA4: cytotoxic T-lymphocyte associated protein 4. 
 
Figure 8. Both Tregs and iNKT cells are essential for mixed chimera induction.  
(A) WT or Jα18-/- (iNKT-cell deficient) BALB/c mice were transplanted with WT B6 bone 
marrow with αGC-liposomes plus anti-CD40L. In the Treg-depleted group, WT recipient 
mice were injected interaperitoneally with 0.5mg anti-CD25 mAb (PC61.5.3) one day before 
BMT to deplete Tregs. Two weeks after BMT, establishment of chimerism was assessed by 
flow-cytometer indicating % of donor cells in PBMCs of individual mice. (B) Both WT 
recipient mice (N=4) and iNKT-deficient recipient mice (N=4) were sacrificed 30 d after 
BMT; Tregs in the splenocytes were analyzed. Top, representative dot plots of cells gated 
by CD4 positive cells. Bottom, representative histogram of Ki-67 expression in the cells 
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